Simultaneous Intramuscular And Intranasal Administration Of Chitosan Nanoparticles–Adjuvanted Chlamydia Vaccine Elicits Elevated Protective Responses In The Lung

References

• Knittler MR, Berndt A, Bocker S, et al. Chlamydia psittaci: new insights into genomic diversity, clinical pathology, host-pathogen interaction and anti-bacterial immunity. Int J Med Microbiol. 2014;304(7):877–893. doi:10.1016/j.ijmm.2014.06.01025082204
   PubMed Web of Science ®Google Scholar
• Knittler MR, Sachse K. Chlamydia psittaci: update on an underestimated zoonotic agent. Pathog Dis. 2015;73(1):1–15. doi:10.1093/femspd/ftu007
   PubMed Web of Science ®Google Scholar
• Beeckman DS, Vanrompay DC. Zoonotic Chlamydophila psittaci infections from a clinical perspective. Clin Microbiol Infe. 2009;15(1):11–17. doi:10.1111/j.1469-0691.2008.02669.x
   PubMed Web of Science ®Google Scholar
• Chu J, Zhang Q, Zhang T, et al. Chlamydia psittaci infection increases mortality of avian influenza virus H9N2 by suppressing host immune response. Sci Rep. 2016;6:29421. doi:10.1038/srep2942127405059
   PubMedGoogle Scholar
• Longbottom D, Livingstone M. Vaccination against chlamydial infections of man and animals. Vet J. 2006;171(2):263–275. doi:10.1016/j.tvjl.2004.09.00616490708
   PubMed Web of Science ®Google Scholar
• Farris CM, Morrison RP. Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model. Infect Immun. 2011;79(3):986–996. doi:10.1128/IAI.00881-1021078844
   PubMed Web of Science ®Google Scholar
• Liang M, Wen Y, Ran O, et al. Protective immunity induced by recombinant protein CPSIT_p8 of Chlamydia psittaci. Appl Microbiol Biot. 2016;100(14):6385–6393. doi:10.1007/s00253-016-7494-8
   PubMed Web of Science ®Google Scholar
• Zhou J, Qiu C, Cao XA, Lin G. Construction and immunogenicity of recombinant adenovirus expressing the major outer membrane protein (MOMP) of Chlamydophila psittaci in chicks. Vaccine. 2007;25(34):6367–6372. doi:10.1016/j.vaccine.2007.06.03117640776
   PubMedGoogle Scholar
• Tan Y, Li Y, Zhang Y, et al. Immunization with Chlamydia psittaci plasmid-encoded protein CPSIT_p7 induces partial protective immunity against chlamydia lung infection in mice. Immunol Res. 2018;66(4):471–479. doi:10.1007/s12026-018-9018-330097797
   PubMedGoogle Scholar
• Li Y, Zheng K, Tan Y, et al. A recombinant multi-epitope peptide vaccine based on MOMP and CPSIT_p6 protein protects against Chlamydia psittaci lung infection. Appl Microbiol Biot. 2019;103(2):941–952. doi:10.1007/s00253-018-9513-4
   PubMed Web of Science ®Google Scholar
• Samanta GP. Mathematical analysis of a Chlamydia epidemic model with pulse vaccination strategy. Acta Biotheor. 2015;63(1):1–21. doi:10.1007/s10441-014-9234-825077807
   PubMedGoogle Scholar
• Bode J, Dutow P, Sommer K, et al. A new role of the complement system: C3 provides protection in a mouse model of lung infection with intracellular Chlamydia psittaci. PloS One. 2012;7(11):e50327. doi:10.1371/journal.pone.005032723189195
   PubMedGoogle Scholar
• Moore T, Ekworomadu CO, Eko FO, et al. Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J Infect Dis. 2003;188(4):617–624. doi:10.1086/37713412898452
   PubMed Web of Science ®Google Scholar
• Farris CM, Morrison SG, Morrison RP. CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection. Infect Immun. 2010;78(10):4374–4383. doi:10.1128/IAI.00622-1020660610
   PubMed Web of Science ®Google Scholar
• Jaffar Z, Ferrini ME, Herritt LA, Roberts K. Cutting edge: lung mucosal Th17-mediated responses induce polymeric Ig receptor expression by the airway epithelium and elevate secretory IgA levels. J Immunol. 2009;182(8):4507–4511. doi:10.4049/jimmunol.090023719342622
   PubMedGoogle Scholar
• Badamchi-Zadeh A, McKay PF, Holland MJ, et al. Intramuscular immunisation with chlamydial proteins induces Chlamydia trachomatis specific ocular antibodies. PLoS One. 2015;10(10):e0141209. doi:10.1371/journal.pone.014120926501198
   PubMedGoogle Scholar
• Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006;6(2):148–158. doi:10.1038/nri177716491139
   PubMed Web of Science ®Google Scholar
• Zariwala MG, Bendre H, Markiv A, et al. Hydrophobically modified chitosan nanoliposomes for intestinal drug delivery. Int J Nanomed. 2018;13:5837–5848. doi:10.2147/IJN.S166901
   PubMed Web of Science ®Google Scholar
• Hassan UA, Hussein MZ, Alitheen NB, Yahya Ariff SA, Masarudin MJ. In vitro cellular localization and efficient accumulation of fluorescently tagged biomaterials from monodispersed chitosan nanoparticles for elucidation of controlled release pathways for drug delivery systems. Int J Nanomed. 2018;13:5075–5095. doi:10.2147/IJN.S164843
   PubMed Web of Science ®Google Scholar
• Frank LA, Sandri G, D’Autilia F, et al. Chitosan gel containing polymeric nanocapsules: a new formulation for vaginal drug delivery. Int J Nanomed. 2014;9:3151–3161.
   PubMed Web of Science ®Google Scholar
• Bento D, Staats HF, Goncalves T, Borges O. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity. Eur J Pharm Biopharm. 2015;93:149–164. doi:10.1016/j.ejpb.2015.03.02425818119
   PubMed Web of Science ®Google Scholar
• Malik A, Gupta M, Gupta V, Gogoi H, Bhatnagar R. Novel application of trimethyl chitosan as an adjuvant in vaccine delivery. Int J Nanomed. 2018;13:7959–7970. doi:10.2147/IJN.S165876
   PubMed Web of Science ®Google Scholar
• Dhakal S, Renu S, Ghimire S, et al. Mucosal immunity and protective efficacy of intranasal inactivated influenza vaccine is improved by chitosan nanoparticle delivery in pigs. Front Immunol. 2018;9:934. doi:10.3389/fimmu.2018.0093429770135
   PubMed Web of Science ®Google Scholar
• Malik A, Gupta M, Mani R, Gogoi H, Bhatnagar R. Trimethyl chitosan nanoparticles encapsulated protective antigen protects the mice against anthrax. Front Immunol. 2018;9:562. doi:10.3389/fimmu.2018.0056229616046
   PubMed Web of Science ®Google Scholar
• Da Silva RL, Da Silva JR, Junior APD, et al. Adsorption of vi capsular antigen of salmonella typhi in chitosan-poly (methacrylic acid) nanoparticles. Polymers. 2019;11(7):E1226. doi:10.3390/polym1107122631340432
   PubMedGoogle Scholar
• Dutow P, Fehlhaber B, Bode J, et al. The complement C3a receptor is critical in defense against Chlamydia psittaci in mouse lung infection and required for antibody and optimal T cell response. J Infect Dis. 2014;209(8):1269–1278. doi:10.1093/infdis/jit64024273177
   PubMed Web of Science ®Google Scholar
• Wen Y, Chen Y, Li L, et al. Localization and characterization of a putative cysteine desulfurase in Chlamydia psittaci. J Cell Biochem. 2019;120(3):4409–4422. doi:10.1002/jcb.2772730260037
   PubMedGoogle Scholar
• Zheng K, Xu M, Xiao Y, et al. Immunogenicity and protective efficacy against Treponema pallidum in New Zealand rabbits immunized with plasmid DNA encoding flagellin. Emerg Microbes Infec. 2018;7(1):177. doi:10.1038/s41426-018-0176-030405111
   PubMedGoogle Scholar
• Stepanova LA, Kotlyarov RY, Kovaleva AA, et al. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin. PLoS One. 2015;10(3):e0119520. doi:10.1371/journal.pone.011952025799221
   PubMedGoogle Scholar
• Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1(2):135–145. doi:10.1038/3510052911905821
   PubMed Web of Science ®Google Scholar
• van Drunen Littel-van Den Hurk S, Gerdts V, Loehr BI, et al. Recent advances in the use of DNA vaccines for the treatment of diseases of farmed animals. Adv Drug Deliver Rev. 2000;43(1):13–28. doi:10.1016/S0169-409X(00)00074-0
   PubMed Web of Science ®Google Scholar
• Nogueira CV, Zhang X, Giovannone N, Sennott EL, Starnbach MN. Protective immunity against Chlamydia trachomatis can engage both CD4+ and CD8+ T cells and bridge the respiratory and genital mucosae. J Immunol. 2015;194(5):2319–2329. doi:10.4049/jimmunol.140267525637024
   PubMed Web of Science ®Google Scholar
• Tammiruusu A, Penttila T, Lahesmaa R, Sarvas M, Puolakkainen M, Vuola JM. Intranasal administration of chlamydial outer protein N (CopN) induces protection against pulmonary Chlamydia pneumoniae infection in a mouse model. Vaccine. 2007;25(2):283–290. doi:10.1016/j.vaccine.2006.07.04316949182
   PubMedGoogle Scholar
• Ciabattini A, Prota G, Christensen D, Andersen P, Pozzi G, Medaglini D. Characterization of the antigen-specific CD4(+) T cell response induced by prime-boost strategies with CAF01 and CpG adjuvants administered by the intranasal and subcutaneous routes. Front Immunol. 2015;6:430. doi:10.3389/fimmu.2015.0043026379666
   PubMedGoogle Scholar
• Christensen D, Mortensen R, Rosenkrands I, Dietrich J, Andersen P. Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses. Mucosal Immunol. 2017;10(1):260–270. doi:10.1038/mi.2016.2827049058
   PubMed Web of Science ®Google Scholar
• Mehrabi M, Montazeri H, Mohamadpour Dounighi N, Rashti A, Vakili-Ghartavol R. Chitosan-based nanoparticles in mucosal vaccine delivery. Arch Razi Inst. 2018;73(3):165–176. doi:10.22092/ari.2017.109235.110130280836
   PubMedGoogle Scholar
• Sun T, Zhan B, Zhang W, et al. Carboxymethyl chitosan nanoparticles loaded with bioactive peptide OH-CATH30 benefit nonscar wound healing. Int J Nanomed. 2018;13:5771–5786. doi:10.2147/IJN.S156206
   PubMed Web of Science ®Google Scholar
• van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan for mucosal vaccination. Adv Drug Deliver Rev. 2001;52(2):139–144. doi:10.1016/S0169-409X(01)00197-1
   PubMed Web of Science ®Google Scholar
• Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnol. 2011;9:55. doi:10.1186/1477-3155-9-55
   PubMed Web of Science ®Google Scholar
• Mishra N, Goyal AK, Tiwari S, et al. Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers. Expert Opin Ther Pat. 2010;20(5):661–679. doi:10.1517/1354377100373042520345332
   PubMed Web of Science ®Google Scholar
• Khan SA, Polkinghorne A, Waugh C, et al. Humoral immune responses in koalas (Phascolarctos cinereus) either naturally infected with Chlamydia pecorum or following administration of a recombinant chlamydial major outer membrane protein vaccine. Vaccine. 2016;34(6):775–782. doi:10.1016/j.vaccine.2015.12.05026747718
   PubMedGoogle Scholar
• Pickering H, Teng A, Faal N, et al. Genome-wide profiling of humoral immunity and pathogen genes under selection identifies immune evasion tactics of Chlamydia trachomatis during ocular infection. Sci Rep. 2017;7(1):9634. doi:10.1038/s41598-017-09193-228851925
   PubMedGoogle Scholar
• De Clercq E, Devriendt B, Yin L, Chiers K, Cox E, Vanrompay D. The immune response against Chlamydia suis genital tract infection partially protects against re-infection. Vet Res. 2014;45:95. doi:10.1186/s13567-014-0095-625252649
   PubMed Web of Science ®Google Scholar
• Fahrbach KM, Malykhina O, Stieh DJ, Hope TJ. Differential binding of IgG and IgA to mucus of the female reproductive tract. PLoS One. 2013;8(10):e76176. doi:10.1371/journal.pone.007617624098437
   PubMed Web of Science ®Google Scholar
• Renegar KB, Jackson GD, Mestecky J. In vitro comparison of the biologic activities of monoclonal monomeric IgA, polymeric IgA, and secretory IgA. J Immunol. 1998;160(3):1219–1223.9570537
   PubMed Web of Science ®Google Scholar
• Zhu C, Lin H, Tang L, Chen J, Wu Y, Zhong G. Oral Chlamydia vaccination induces transmucosal protection in the airway. Vaccine. 2018;36(16):2061–2068. doi:10.1016/j.vaccine.2018.03.01529550196
   PubMed Web of Science ®Google Scholar
• Karunakaran KP, Yu H, Foster LJ, Brunham RC. Development of a Chlamydia trachomatis T cell Vaccine. Hum Vaccines. 2010;6(8):676–680. doi:10.4161/hv.6.8.12299
   PubMed Web of Science ®Google Scholar
• Pal S, de la Maza LM. Mechanism of T-cell mediated protection in newborn mice against a Chlamydia infection. Microbes Infect. 2013;15(8–9):607–614. doi:10.1016/j.micinf.2013.04.01023644176
   PubMedGoogle Scholar
• Quispe Calla NE, Vicetti Miguel RD, Mei A, Fan S, Gilmore JR, Cherpes TL. Dendritic cell function and pathogen-specific T cell immunity are inhibited in mice administered levonorgestrel prior to intranasal Chlamydia trachomatis infection. Sci Rep. 2016;6:37723. doi:10.1038/srep3772327892938
   PubMedGoogle Scholar
• Ralli-Jain P, Tifrea D, Cheng C, Pal S, de la Maza LM. Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization. Vaccine. 2010;28(48):7659–7666. doi:10.1016/j.vaccine.2010.09.04020875490
   PubMed Web of Science ®Google Scholar
• Jupelli M, Guentzel MN, Meier PA, Zhong G, Murthy AK, Arulanandam BP. Endogenous IFN-gamma production is induced and required for protective immunity against pulmonary chlamydial infection in neonatal mice. J Immunol. 2008;180(6):4148–4155. doi:10.4049/jimmunol.180.6.414818322226
   PubMedGoogle Scholar
• Rottenberg ME, Gigliotti Rothfuchs AC, Gigliotti D, Svanholm C, Bandholtz L, Wigzell H. Role of innate and adaptive immunity in the outcome of primary infection with Chlamydia pneumoniae, as analyzed in genetically modified mice. J Immunol. 1999;162(5):2829–2836.10072530
   PubMed Web of Science ®Google Scholar
• Verma R, Sahu R, Dixit S, et al. The Chlamydia M278 Major Outer Membrane Peptide Encapsulated in the Poly (lactic acid)-Poly (ethylene glycol) Nanoparticulate Self-Adjuvanting Delivery System Protects Mice Against a Chlamydia muridarum Genital Tract Challenge by Stimulating Robust Systemic and Local Mucosal Immune Responses. Front Immunol. 2018;9:2369.30374357
   PubMed Web of Science ®Google Scholar
• Wern JE, Sorensen MR, Olsen AW, Andersen P, Follmann F. Simultaneous subcutaneous and intranasal administration of a CAF01-adjuvanted Chlamydia vaccine elicits elevated IgA and protective Th1/Th17 responses in the genital tract. Front Immunol. 2017;8:569. doi:10.3389/fimmu.2017.0056928567043
   PubMed Web of Science ®Google Scholar
• Reinhold P, Ostermann C, Liebler-Tenorio E, et al. A bovine model of respiratory Chlamydia psittaci infection: challenge dose titration. PLoS One. 2012;7(1):e30125. doi:10.1371/journal.pone.003012522299031
   PubMedGoogle Scholar
• Hogerwerf L, De Gier B, Baan B, Van Der Hoek W. Chlamydia psittaci (psittacosis) as a cause of community-acquired pneumonia: a systematic review and meta-analysis. Epidemiol Infect. 2017;145(15):3096–3105. doi:10.1017/S095026881700206028946931
   PubMed Web of Science ®Google Scholar